Kintara Therapeutics, Inc. Stock price

Equities

KTRA

US49720K2006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:10:29 2024-03-28 am EDT 5-day change 1st Jan Change
0.101 USD +12.85% Intraday chart for Kintara Therapeutics, Inc. +10.38% -40.45%
Sales 2022 - Sales 2023 - Capitalization 6.82M
Net income 2022 -22M Net income 2023 -14M EV / Sales 2022 -
Net cash position 2022 11.78M Net cash position 2023 2.61M EV / Sales 2023 -
P/E ratio 2022
-0.54 x
P/E ratio 2023
-0.43 x
Employees 2
Yield 2022 *
-
Yield 2023
-
Free-Float 99.79%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Kintara Therapeutics, Inc.

1 day+26.26%
1 week-0.67%
Current month-16.36%
1 month-10.41%
3 months-50.28%
6 months-97.87%
Current year-47.23%
More quotes
1 week
0.09
Extreme 0.086
0.10
1 month
0.08
Extreme 0.081
0.13
Current year
0.08
Extreme 0.081
0.18
1 year
0.08
Extreme 0.081
5.98
3 years
0.08
Extreme 0.081
142.50
5 years
0.08
Extreme 0.081
287.50
10 years
0.08
Extreme 0.081
5 435.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 18-04-10
Chief Operating Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 58 18-04-10
Director/Board Member 65 21-04-28
Director/Board Member 59 20-06-25
More insiders
Date Price Change Volume
24-03-28 0.1006 +12.40% 22 512 514
24-03-27 0.0895 -0.33% 5,259,034
24-03-26 0.0898 +0.79% 2,532,528
24-03-25 0.0891 -2.62% 2,134,937
24-03-22 0.0915 0.00% 3,003,083

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.
More about the company
  1. Stock
  2. Equities
  3. Stock Kintara Therapeutics, Inc. - Nasdaq